NXNingning Xue

Ningning Xue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ningning Xue has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Yuemin Nan

    Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, China

    3 shared publications
  • Lingdi Liu

    Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, China

    2 shared publications
  • Lu Li

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital & Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang, Hebei Province, 050051, People’s Republic of China

    2 shared publications
  • Wen Zhao

    Department of Infectious Diseases The First Affiliated Hospital of Bengbu Medical University Bengbu China

    2 shared publications
  • Xiaoxiao Zhang

    Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University & Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang, Hebei, China

    2 shared publications
  • Yuhui Tang

    Department of Traditional and Western Medical Hepatology Third Hospital of Hebei Medical University Shijiazhuang China

    2 shared publications

Latest Publications

  • Open Access

    Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study

    by Wencong Li, Jing Liang, Jihong An, Lingdi Liu, Yihui Hou, Lu Li, Wen Zhao, Luyao Cui, Ningning Xue, Zaid Al-Dhamin, et al.

    Objective. To assess the geographic distribution of HCV genotypes, effectiveness, and safety of DAA treatment for HCV-infected patients in North and Northeast China. Methods. The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustained virologic response rates at 12 (SVR12) or 24 (SVR24) weeks posttreatment and safety were analyzed in 405 patients who completed DAA treatment according to patient baseline characteristics and treatment. Results. Four genotypes and six subtypes were identified as follows: 1b (1187, 54.90%), 2a (790, 36.54%), 3a/b (134, 6.20%), 6a/n (44, 2.04%), mixed genotypes (2a-6a or 2a-3a) (7, 0.32%). Overall, 99.01% patients achieved SVR12, while 98.43% achieved SVR24. All patients treated with elbasvir/grazoprevir (EBR/GZR), sofosbuvir/velpatasvir ± ribavirin (SOF/VEL ± RBV), and SOF/ledipasvir (LDV) achieved SVR12 or SVR24; 92.86% SVR12 and 95.83% SVR24 were observed in patients using SOF + RBV. SVR12 was higher in noncirrhosis versus compensated cirrhosis patients (100% vs. 97.09%, ). No severe drug-related adverse event was observed. Conclusions. Genotypes 1b and 2a were dominant subtypes in North and Northeast China. The approved drug regimens EBR/GZR and SOF/LDV for subtype 1b and SOF/VEL for nongenotype 1b are the optimal effective and safety profile.


  • Identification of potential plasma markers for hepatitis B virus‐related chronic hepatitis and liver fibrosis/cirrhosis

    by Dandan Zhao, Songhao Yu, Peilin Guo, Xiaoxiao Zhang, Yuhui Tang, Chen Dong, Suxian Zhao, Lu Li, Zaid Al‐Dhamin, Rong Ai, et al.

    The aim of this study was to identify potential plasma biomarkers for hepatitis B virus (HBV)‐related liver diseases. High‐throughput transcriptome sequencing analysis was performed on five patients with chronic hepatitis B (CHB), five patients with HBV‐associated liver fibrosis/liver cirrhosis (LF/LC), and four healthy participants. By short time‐series expression miner and functional analysis, aquaporin 1 (AQP1), dystroglycan 1 (DAG1), and hemoglobin subunit beta (HBB) were identified as potential biomarkers. Immunohistochemical analysis revealed that the expression levels of AQP1, DAG1, and HBB were upregulated in the three groups. Subsequent enzyme‐linked immunosorbent assay tests on the training cohort ( n = 150) indicated that the plasma levels of AQP1 and DAG1 were highest in LF/LC patients, followed by those in CHB patients, and the lowest in healthy controls. APAD model, a diagnostic panel incorporating age, platelet, AQP1, and DAG1 levels, exhibited the strongest stratification ability to distinguish LF/LC patients from CHB patients, and to differentiate CHB patients from healthy controls. Furthermore, the diagnostic accuracies of the biomarkers and APAD model were verified in an independent cohort consisting of 230 participants. In conclusion, both AQP1 and DAG1 have good diagnostic values and APAD model greatly enhances the diagnostic accuracy for HBV‐related hepatic diseases.


  • Plasma Yap1 Predicts Esophageal Varices and The Risk of Variceal Bleeding in Liver Cirrhosis

    by Wen Zhao, Ningning Xue, Po Cui, Lingdi Liu, Yiqi Wang, Xiaoxiao Zhang, Yuhui Tang, Huijuan Du, Yuemin Nan

    Aim: To explore the predictive value of plasma YAP1 for esophageal varices (EV) and high-risk EV (HRV) in patients with liver cirrhosis. Materials & methods: A total of 208 patients with liver cirr...